Silverarc Capital Management’s ESSA Pharma EPIX Stock Holding History

Silverarc Capital Management’s Portfolio EPIX Stock Details EPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-73,451	Closed	-$2.13M	–	105
2021 Q1	$2.13M	Sell	73,451 -249,466	-77%	-$5.8M	1.16%	33
2020 Q4	$3.85M	Buy	+322,917	New	+$2.27M	2.24%	17

Other funds holding EPIX

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Silverarc Capital Management's EPIX Position: Q2 2021 in Review

Silverarc Capital Management sold out of ESSA Pharma (EPIX) in Q2 2021, closing a stake of 73,451 shares — an estimated $2.13M sold.

Silverarc Capital Management first reported a position in EPIX in Q4 2020 and held it in 2 quarters. The position peaked at $3.85M in Q4 2020. 80 funds tracked by Wall St. Rank hold EPIX as of Q2 2021.

Silverarc Capital Management reported no remaining ESSA Pharma position as of Q2 2021 after selling out during the quarter.
Silverarc Capital Management sold 73,451 ESSA Pharma shares in Q2 2021, an estimated $2.13M.
Silverarc Capital Management first reported a position in ESSA Pharma in Q4 2020 and held it in 2 quarters.
Silverarc Capital Management's ESSA Pharma position peaked at $3.85M in Q4 2020.
80 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2021.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.